These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27443592)

  • 21. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
    J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.
    Doherty JF; Pinder M; Tornieporth N; Carton C; Vigneron L; Milligan P; Ballou WR; Holland CA; Kester KE; Voss G; Momin P; Greenwood BM; McAdam KP; Cohen J
    Am J Trop Med Hyg; 1999 Dec; 61(6):865-8. PubMed ID: 10674660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
    Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
    Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
    Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
    Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans.
    Kazmin D; Nakaya HI; Lee EK; Johnson MJ; van der Most R; van den Berg RA; Ballou WR; Jongert E; Wille-Reece U; Ockenhouse C; Aderem A; Zak DE; Sadoff J; Hendriks J; Wrammert J; Ahmed R; Pulendran B
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2425-2430. PubMed ID: 28193898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
    Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
    Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.
    Alloueche A; Milligan P; Conway DJ; Pinder M; Bojang K; Doherty T; Tornieporth N; Cohen J; Greenwood BM
    Am J Trop Med Hyg; 2003 Jan; 68(1):97-101. PubMed ID: 12556156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
    Ajua A; Lell B; Agnandji ST; Asante KP; Owusu-Agyei S; Mwangoka G; Mpina M; Salim N; Tanner M; Abdulla S; Vekemans J; Jongert E; Lievens M; Cambron P; Ockenhouse CF; Kremsner PG; Mordmüller B
    Malar J; 2015 Feb; 14():72. PubMed ID: 25885325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
    Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
    Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.
    Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C
    BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
    Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Daniel S; Pichugin A; Torano H; Renn JP; Kwan J; Cowles MV; Conteh S; Lambert LE; Alani N; MacDonald NJ; Dai W; Highsmith K; Anderson C; Gorres JP; Musgrove J; Butler B; Althubaiti N; Dixit S; Zarling-Bejma S; Krzych U; Duffy PE
    Infect Immun; 2021 Oct; 89(11):e0016521. PubMed ID: 34310889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
    Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
    Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.
    Moris P; Jongert E; van der Most RG
    Hum Vaccin Immunother; 2018 Jan; 14(1):17-27. PubMed ID: 28934066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.
    Foquet L; Hermsen CC; van Gemert GJ; Van Braeckel E; Weening KE; Sauerwein R; Meuleman P; Leroux-Roels G
    J Clin Invest; 2014 Jan; 124(1):140-4. PubMed ID: 24292709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
    Bojang KA; Olodude F; Pinder M; Ofori-Anyinam O; Vigneron L; Fitzpatrick S; Njie F; Kassanga A; Leach A; Milman J; Rabinovich R; McAdam KP; Kester KE; Heppner DG; Cohen JD; Tornieporth N; Milligan PJ
    Vaccine; 2005 Jul; 23(32):4148-57. PubMed ID: 15964483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
    Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
    Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RTS,S/AS02A Malaria Vaccine-Induced IgG Responses Equally Recognize Native-Like Fucosylated and Nonfucosylated Plasmodium falciparum Circumsporozoite Proteins.
    Jairoce C; Macià D; Torres-Yaguana JP; Mayer L; Vidal M; Santano R; Hurtado-Guerrero R; Reiter K; Narum DL; Lopez-Gutierrez B; Hamerly T; Sacarlal J; Aguilar R; Dinglasan RR; Moncunill G; Izquierdo L; Dobaño C
    J Infect Dis; 2024 Mar; 229(3):795-799. PubMed ID: 37889513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.